Cytyc
This article was originally published in The Gray Sheet
Executive Summary
Prudential Health Plans joins a growing list of third party payers that are reimbursing for the ThinPrep Pap Test for cervical cancer screening, the company told investors at a June 9 Piper Jaffray conference in Minneapolis. The test, which sells at a list price of $475 for 40 tests, has been accepted for reimbursement by independent Blue Cross and Blue Shield health plans in New York (Empire), North Carolina, Maryland, Montana, and West Virginia (Mountain State) and by Oxford Health Plans. Pennsylvania-based Highmark Blue Cross and Blue Shield rejected a reimbursement request by Cytyc earlier this year citing a lack of evidence to demonstrate cost effectiveness of the device ("The Gray Sheet" Feb. 16, p. 9). Cytyc is considering seeking labeling to allow for screening for common sexually transmitted diseases